---
document_datetime: 2025-12-02 06:00:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/giapreza.html
document_name: giapreza.html
version: success
processing_time: 0.1166329
conversion_datetime: 2025-12-24 04:53:37.125076
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Giapreza

[RSS](/en/individual-human-medicine.xml/67230)

##### Authorised

This medicine is authorised for use in the European Union

angiotensin II Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Giapreza](#news-on)
- [More information on Giapreza](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Giapreza is a medicine used in adults with dangerously low blood pressure (a condition known as shock).

It is used when other treatments for raising blood pressure have not worked and contains the active substance angiotensin II.

Expand section

Collapse section

## How is Giapreza used?

The medicine should be prescribed by a physician experienced in the treatment of shock and is for use in a hospital setting. It is given as a continuous infusion ('drip') into a vein. The dose depends on the patient's weight and should be adjusted according to the patient's blood pressure.

For more information about using Giapreza, see the package leaflet or contact your doctor or pharmacist.

## How does Giapreza work?

The active substance in Giapreza, angiotensin II, is the same as a hormone that the body produces. Angiotensin II increases blood pressure by narrowing blood vessels and releasing another hormone (aldosterone) that increases the volume of blood circulating in the body.

## What benefits of Giapreza have been shown in studies?

A main study involving 344 patients in shock has shown that Giapreza is effective at raising blood pressure when other treatments have not worked. After 3 hours, 70% of patients treated with Giapreza in addition to standard treatments had their average arterial blood pressure rise to above 75 mmHg (an acceptable level) or by at least 10 mmHg, compared with 23% of patients treated with placebo (a dummy treatment) and standard treatments.

## What are the risks associated with Giapreza?

The most common side effects with Giapreza (which may affect more than 1 in 10 people) are thromboembolic events (problems due to clots in blood vessels) and short-lived high blood pressure.

For the full list of side effects and restrictions with Giapreza, see the package leaflet.

## Why is Giapreza authorised in the EU?

The main study showed that adding Giapreza to standard treatment was effective in increasing average blood pressure in patients in shock. The rise in blood pressure is expected to help prevent organ damage and reduce the number of deaths from this condition. The side effects of Giapreza were similar to those of standard treatments and were considered manageable. The European Medicines Agency therefore decided that Giapreza's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Giapreza?

The company that markets Giapreza will carry out a study to further investigate the effectiveness and safety of Giapreza, including whether the medicine could prevent damage to organs and affect how long patients live.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Giapreza have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Giapreza are continuously monitored. Side effects reported with Giapreza are carefully evaluated and any necessary action taken to protect patients.

## Other information about Giapreza

Giapreza received a marketing authorisation valid throughout the EU on 23 August 2019.

Giapreza : EPAR - Medicine overview

Reference Number: EMA/370784/2019

English (EN) (80.09 KB - PDF)

**First published:** 10/10/2019

[View](/en/documents/overview/giapreza-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-583)

български (BG) (110.03 KB - PDF)

**First published:**

10/10/2019

[View](/bg/documents/overview/giapreza-epar-medicine-overview_bg.pdf)

español (ES) (78.55 KB - PDF)

**First published:**

10/10/2019

[View](/es/documents/overview/giapreza-epar-medicine-overview_es.pdf)

čeština (CS) (101.13 KB - PDF)

**First published:**

10/10/2019

[View](/cs/documents/overview/giapreza-epar-medicine-overview_cs.pdf)

dansk (DA) (76.99 KB - PDF)

**First published:**

10/10/2019

[View](/da/documents/overview/giapreza-epar-medicine-overview_da.pdf)

Deutsch (DE) (78.49 KB - PDF)

**First published:**

10/10/2019

[View](/de/documents/overview/giapreza-epar-medicine-overview_de.pdf)

eesti keel (ET) (77.09 KB - PDF)

**First published:**

10/10/2019

[View](/et/documents/overview/giapreza-epar-medicine-overview_et.pdf)

ελληνικά (EL) (110.84 KB - PDF)

**First published:**

10/10/2019

[View](/el/documents/overview/giapreza-epar-medicine-overview_el.pdf)

français (FR) (78.67 KB - PDF)

**First published:**

10/10/2019

[View](/fr/documents/overview/giapreza-epar-medicine-overview_fr.pdf)

hrvatski (HR) (97.21 KB - PDF)

**First published:**

10/10/2019

[View](/hr/documents/overview/giapreza-epar-medicine-overview_hr.pdf)

italiano (IT) (77.51 KB - PDF)

**First published:**

10/10/2019

[View](/it/documents/overview/giapreza-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (106.69 KB - PDF)

**First published:**

10/10/2019

[View](/lv/documents/overview/giapreza-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (99.22 KB - PDF)

**First published:**

10/10/2019

[View](/lt/documents/overview/giapreza-epar-medicine-overview_lt.pdf)

magyar (HU) (95.61 KB - PDF)

**First published:**

10/10/2019

[View](/hu/documents/overview/giapreza-epar-medicine-overview_hu.pdf)

Malti (MT) (108.85 KB - PDF)

**First published:**

10/10/2019

[View](/mt/documents/overview/giapreza-epar-medicine-overview_mt.pdf)

Nederlands (NL) (31.99 KB - PDF)

**First published:**

10/10/2019

[View](/nl/documents/overview/giapreza-epar-medicine-overview_nl.pdf)

polski (PL) (101.09 KB - PDF)

**First published:**

10/10/2019

[View](/pl/documents/overview/giapreza-epar-medicine-overview_pl.pdf)

português (PT) (32.28 KB - PDF)

**First published:**

10/10/2019

[View](/pt/documents/overview/giapreza-epar-medicine-overview_pt.pdf)

română (RO) (105.02 KB - PDF)

**First published:**

10/10/2019

[View](/ro/documents/overview/giapreza-epar-medicine-overview_ro.pdf)

slovenčina (SK) (100.83 KB - PDF)

**First published:**

10/10/2019

[View](/sk/documents/overview/giapreza-epar-medicine-overview_sk.pdf)

slovenščina (SL) (95.37 KB - PDF)

**First published:**

10/10/2019

[View](/sl/documents/overview/giapreza-epar-medicine-overview_sl.pdf)

Suomi (FI) (77.37 KB - PDF)

**First published:**

10/10/2019

[View](/fi/documents/overview/giapreza-epar-medicine-overview_fi.pdf)

svenska (SV) (78.15 KB - PDF)

**First published:**

10/10/2019

[View](/sv/documents/overview/giapreza-epar-medicine-overview_sv.pdf)

Giapreza : EPAR - Risk-management-plan summary

English (EN) (239.1 KB - PDF)

**First published:** 10/10/2019

[View](/en/documents/rmp-summary/giapreza-epar-risk-management-plan-summary_en.pdf)

## Product information

Giapreza : EPAR - Product Information

English (EN) (266.83 KB - PDF)

**First published:** 10/10/2019

**Last updated:** 25/09/2024

[View](/en/documents/product-information/giapreza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-213)

български (BG) (332.35 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/bg/documents/product-information/giapreza-epar-product-information_bg.pdf)

español (ES) (255.55 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/es/documents/product-information/giapreza-epar-product-information_es.pdf)

čeština (CS) (310.25 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/cs/documents/product-information/giapreza-epar-product-information_cs.pdf)

dansk (DA) (256.3 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/da/documents/product-information/giapreza-epar-product-information_da.pdf)

Deutsch (DE) (258.6 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/de/documents/product-information/giapreza-epar-product-information_de.pdf)

eesti keel (ET) (256.95 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/et/documents/product-information/giapreza-epar-product-information_et.pdf)

ελληνικά (EL) (335.01 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/el/documents/product-information/giapreza-epar-product-information_el.pdf)

français (FR) (321.37 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/fr/documents/product-information/giapreza-epar-product-information_fr.pdf)

hrvatski (HR) (310.17 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/hr/documents/product-information/giapreza-epar-product-information_hr.pdf)

íslenska (IS) (259.19 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/is/documents/product-information/giapreza-epar-product-information_is.pdf)

italiano (IT) (264.32 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/it/documents/product-information/giapreza-epar-product-information_it.pdf)

latviešu valoda (LV) (304.85 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/lv/documents/product-information/giapreza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (319.5 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/lt/documents/product-information/giapreza-epar-product-information_lt.pdf)

magyar (HU) (321.47 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/hu/documents/product-information/giapreza-epar-product-information_hu.pdf)

Malti (MT) (337.24 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/mt/documents/product-information/giapreza-epar-product-information_mt.pdf)

Nederlands (NL) (253.95 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/nl/documents/product-information/giapreza-epar-product-information_nl.pdf)

norsk (NO) (248.41 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/no/documents/product-information/giapreza-epar-product-information_no.pdf)

polski (PL) (318.79 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/pl/documents/product-information/giapreza-epar-product-information_pl.pdf)

português (PT) (251.12 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/pt/documents/product-information/giapreza-epar-product-information_pt.pdf)

română (RO) (312.15 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/ro/documents/product-information/giapreza-epar-product-information_ro.pdf)

slovenčina (SK) (323.06 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/sk/documents/product-information/giapreza-epar-product-information_sk.pdf)

slovenščina (SL) (303.96 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/sl/documents/product-information/giapreza-epar-product-information_sl.pdf)

Suomi (FI) (255.45 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/fi/documents/product-information/giapreza-epar-product-information_fi.pdf)

svenska (SV) (247.98 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

25/09/2024

[View](/sv/documents/product-information/giapreza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0031 19/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Giapreza : EPAR - All authorised presentations

English (EN) (7.22 KB - PDF)

**First published:** 10/10/2019

**Last updated:** 23/03/2021

[View](/en/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-348)

български (BG) (31.01 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/bg/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_bg.pdf)

español (ES) (8.03 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/es/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.13 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/cs/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (8.64 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/da/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (8.81 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/de/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.03 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/et/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (30.98 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/el/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_el.pdf)

français (FR) (7.69 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/fr/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (26.7 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/hr/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (8.14 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/is/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (7.6 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/it/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (30.04 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/lv/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (28.64 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/lt/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (17.7 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/hu/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.8 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/mt/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (8.2 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/nl/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (8.14 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/no/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.25 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/pl/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_pl.pdf)

português (PT) (8.02 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/pt/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.17 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/ro/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.6 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/sk/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (16.92 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/sl/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (7.62 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/fi/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (7.78 KB - PDF)

**First published:**

10/10/2019

**Last updated:**

23/03/2021

[View](/sv/documents/all-authorised-presentations/giapreza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Giapreza Active substance angiotensin II acetate International non-proprietary name (INN) or common name angiotensin II Therapeutic area (MeSH)

- Hypotension
- Shock

Anatomical therapeutic chemical (ATC) code C09

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

## Authorisation details

EMA product number EMEA/H/C/004930

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Paion Pharma GmbH

Heussstrasse 25 Brand 52078 Aachen GERMANY

Opinion adopted 27/06/2019 Marketing authorisation issued 23/08/2019 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Giapreza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (112.17 KB - PDF)

**First published:** 23/03/2021

**Last updated:** 25/09/2024

[View](/en/documents/procedural-steps-after/giapreza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Giapreza : EPAR - Public assessment report

Adopted

Reference Number: EMA/508753/2019

English (EN) (6.33 MB - PDF)

**First published:** 10/10/2019

[View](/en/documents/assessment-report/giapreza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Giapreza

Adopted

Reference Number: EMA/CHMP/287624/2019

English (EN) (74.57 KB - PDF)

**First published:** 28/06/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-giapreza_en.pdf)

#### News on Giapreza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019) 28/06/2019

#### More information on Giapreza

- [EMEA-001912-PIP02-16-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001912-pip02-16-m03)
- [Giapreza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/giapreza)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/09/2024

## Share this page

[Back to top](#main-content)